Although world of cell & gene therapy, RNA and direct DNA therapies have seen lot of advancement, there has no advancement in manufacturing plasmid DNA for the last 50 years. Today's plasmid DNA industry struggles with poor yields, failed batches, high impurity content and long lead times. Plasmid DNA constitutes the single largest cost center in manufacturing for companies going to the clinic. Novel Biotechnologies has developed world's first non-coli bacterial platform which offers up to 10X yields, preserves the ITRs and PolyA tails, can produce plasmids up to 20 kb in size. The platform offers dramatically reduced impurity loads and up to 50% faster batch times. Too good to be true? come and see the data!